Welcome to our dedicated page for Biodexa Pharmaceuticals Plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals PLC (BDRX) is updating a resale prospectus and disclosing a warrant inducement financing with an existing accredited investor. The supplement continues to cover the resale by selling shareholders of up to 10,950 ordinary shares represented by 219 ADSs.
Separately, the company entered a warrant inducement agreement under which the holder will exercise all outstanding Series M, N and O warrants to purchase an aggregate of 2,204,218 ADSs at an exercise price of $1.05 per ADS. Biodexa expects approximately $2.3 million in gross cash proceeds, before an 8% cash fee to Maxim Group LLC and other expenses. In return, the investor will receive new unregistered Series P warrants to purchase up to 4,408,436 ADSs, also at $1.05 per ADS, exercisable immediately for five years, with standard anti-dilution adjustments and beneficial ownership limits. Biodexa has agreed to file and seek effectiveness of a resale registration statement for the ADSs underlying the Series P warrants within specified 15‑ and 45‑day timeframes, with liquidated damages if these registration or legend‑removal obligations are not met.
Biodexa Pharmaceuticals plc (BDRX) filed a prospectus supplement to its Form F‑1 registration statement covering the resale by a selling shareholder of up to 29,926,150 ordinary shares represented by 598,523 American Depositary Shares (ADSs). The supplement incorporates a Form 6‑K describing a warrant inducement with an accredited holder of the company’s Series M, N and O warrants. The holder is exercising all of its Existing Warrants for an aggregate 2,204,218 ADSs at an exercise price of $1.05 per ADS, and Biodexa expects gross proceeds of about $2.3 million before fees. In return, the holder receives new unregistered Series P warrants to purchase up to 4,408,436 ADSs, also at $1.05 per ADS, exercisable immediately for five years, with standard anti‑dilution adjustments but no price protection. The new warrants are subject to a Beneficial Ownership Limitation of 4.99% or 9.99% and can be exercised on a cashless basis if resale registration is not effective after six months. Biodexa agrees to file a resale registration statement for the ADSs underlying the Series P warrants within 15 days of the agreement and to use commercially reasonable efforts to have it declared effective within 45 days of closing, and will pay Maxim Group LLC an 8% cash fee on the gross proceeds.
Biodexa Pharmaceuticals PLC (BDRX) updated its Form F-1 resale registration to cover up to 127,754,750 ordinary shares represented by 2,555,095 ADSs, issuable upon exercise of previously issued pre-funded, Series M, Series N and Series O warrants by selling shareholders.
Separately, Biodexa entered into a warrant inducement agreement with an accredited holder, reducing the exercise price of its outstanding Series M, N and O warrants being exercised to $1.05 per ADS. The holder is exercising 2,204,218 ADSs, and Biodexa expects to receive approximately $2.3 million in gross proceeds. In consideration, the company will issue Series P warrants for up to 4,408,436 ADSs, exercisable immediately at $1.05 for five years, with anti-dilution adjustments and a beneficial ownership limitation. Biodexa agreed to file a resale registration statement for the ADSs underlying the Series P warrants and pay an 8.0% cash fee on gross proceeds to Maxim Group LLC as warrant solicitation agent.
Biodexa Pharmaceuticals PLC (BDRX) filed a prospectus supplement updating its Form F-1 resale registration for up to 170,150 ordinary shares represented by 3,403 ADSs, to include a recent warrant transaction.
The company entered a warrant inducement agreement with an accredited holder, who agreed to exercise 2,204,218 ADSs of existing Series M, N and O warrants at $1.05 per ADS for anticipated gross proceeds of about $2.3 million, before fees and expenses. In return, the holder will receive new Series P warrants to purchase up to 4,408,436 ADSs at $1.05, exercisable immediately for five years, with customary anti-dilution adjustments and a 4.99% or 9.99% Beneficial Ownership Limitation. Biodexa agreed to file a resale registration statement for the ADSs underlying the new warrants within 15 days and to use commercially reasonable efforts to make it effective within 45 days of closing, with liquidated damages if registration or legend removal is delayed. Maxim Group LLC will receive an 8.0% cash fee on the gross proceeds as warrant solicitation agent.
Biodexa Pharmaceuticals PLC (BDRX) filed a prospectus supplement and Form 6-K describing ongoing registered warrant shares and a new warrant-inducement financing. The registration statement continues to cover up to 97,800 ADSs from pre-funded warrants, 1,219,512 ADSs from Series L warrants, and 30,487 ADSs from placement agent warrants.
Separately, an accredited holder agreed on September 14, 2026 to exercise 2,204,218 ADSs of existing Series M, N and O warrants at $1.05 per ADS, which is expected to provide Biodexa with approximately $2.3 million in gross cash proceeds. In return, the holder will receive new Series P warrants to purchase up to 4,408,436 ADSs at $1.05, exercisable immediately for five years, subject to anti-dilution adjustments and beneficial ownership limits. Biodexa will pay Maxim Group LLC an 8.0% cash fee on gross proceeds and has committed to file a resale registration statement for the ADSs underlying the Series P warrants.
Biodexa Pharmaceuticals PLC (BDRX) filed Prospectus Supplement No. 4 to its Form F-1, which continues to cover the resale by selling shareholders of 17,150 ordinary shares represented by 343 American Depositary Shares (ADSs), and incorporates new disclosure on a warrant inducement transaction.
On September 14, 2026, Biodexa entered into an agreement with an accredited holder of its Series M, N and O warrants to reduce the exercise price of the exercised warrants to $1.05 per ADS. The holder is exercising all of these warrants, resulting in the issuance of 2,204,218 ADSs, and Biodexa expects to receive approximately $2.3 million in gross proceeds, before fees and expenses, with Maxim Group LLC earning an 8.0% cash fee on such proceeds.
In consideration, the investor will receive new unregistered Series P warrants to purchase up to 4,408,436 ADSs at an exercise price of $1.05, which are immediately exercisable and have a five‑year term, subject to standard anti‑dilution adjustments and a Beneficial Ownership Limitation of 4.99% or 9.99%. Biodexa agreed to file a resale registration statement for the ADSs underlying the Series P warrants within 15 days of the agreement and to use commercially reasonable efforts to have it declared effective within 45 days of closing.
Biodexa Pharmaceuticals PLC (BDRX) filed a prospectus supplement updating a resale registration for up to 94,300 ordinary shares represented by 1,886 ADSs, which may be sold from time to time by selling shareholders. This does not involve the company issuing new securities for its own account.
Separately, Biodexa entered into a warrant inducement transaction with an accredited holder of its Series M, N and O warrants. The holder is exercising all existing warrants to purchase an aggregate of 2,204,218 ADSs at an exercise price of $1.05 per ADS, providing expected gross proceeds of approximately $2.3 million, before an 8.0% cash fee to Maxim Group LLC and other expenses. In return, the investor receives new unregistered Series P warrants to purchase up to 4,408,436 ADSs at $1.05, exercisable immediately for five years, with anti-dilution and beneficial ownership limits of 4.99% or 9.99%. Biodexa agreed to register the resale of ADSs underlying the new warrants shortly after closing and may owe liquidated damages if it does not meet the agreed registration and legend-removal timelines.
Biodexa Pharmaceuticals Plc (BDRX) entered into a warrant inducement transaction with an accredited holder of its Series M, N and O warrants. The holder is exercising all of its Existing Warrants to purchase 2,204,218 ADSs at a reduced exercise price of $1.05 per ADS, generating anticipated gross proceeds of about $2.3 million before fees and expenses. In return, the holder will receive new Series P (New) Warrants for up to 4,408,436 ADSs, exercisable immediately at $1.05 per ADS for five years, with standard anti-dilution adjustments but no price protection for future offerings. The ADSs from the Existing Warrants are covered by an effective Form F-1 registration statement, while Biodexa has agreed to file a resale registration statement for the ADSs underlying the New Warrants and may owe liquidated damages if resale registration or legend removals are delayed. Maxim Group LLC will receive a cash fee equal to 8.0% of the gross proceeds as warrant inducement agent and financial advisor.
Biodexa Pharmaceuticals Plc (BDRX) filed a prospectus supplement for the resale by selling shareholders of up to 127,754,750 ordinary shares, represented by 2,555,095 ADSs, issuable upon exercise of outstanding warrants, and reported unaudited interim results for the six months ended June 30, 2026. The company advanced its pipeline, including the registrational Phase 3 “Serenta” trial of eRapa in Familial Adenomatous Polyposis, an investigator-sponsored Phase 2 trial in non-muscle invasive bladder cancer, and in-licensed MTX240, a novel “molecular glue” for GIST. For 1H26, it recorded no revenue, a reduced net loss of £1.84 million and higher R&D investment of £2.92 million, while cash fell to £3.23 million with a net operating cash outflow of £4.61 million. Despite a July 2026 fundraise of $3.5 million and access to an undrawn $26.08 million equity line, management discloses a material uncertainty about going concern, expecting the need for additional financing during Q4 2026 and noting potential risks to continued Nasdaq listing if proposed minimum market value rules take effect.
Biodexa Pharmaceuticals Plc (BDRX) filed a prospectus supplement covering the resale by selling shareholders of up to 17,150 ordinary shares, represented by 343 American Depositary Shares, and concurrently reported unaudited results for the six months ended June 30, 2026.
For 1H26, Biodexa recorded a net loss of £1.84 million, an improvement from £3.81 million in 1H25, on R&D costs of £2.92 million (up 75%) and administrative costs of £1.74 million (down 27%). Finance income was £2.47 million, mainly from a gain on an equity‑settled derivative liability linked to a lower share price. Cash used in operating activities was £4.61 million, leaving £3.23 million of cash at June 30, 2026.
The company advanced its GI cancer pipeline, including a registrational Phase 3 eRapa trial in FAP with 92 of 168 subjects enrolled and in‑licensed MTX240 for GIST. On July 1, 2026 it raised $3.5 million gross via ADS and warrant financing, and has $26.08 million remaining under a $35 million Equity Line of Credit. Directors nonetheless highlight a material uncertainty about going concern, as additional financing is expected to be required during Q4 2026 amid challenging micro‑cap biotech markets and potential Nasdaq minimum market value pressures.